A nurse is caring for a client who has schizophrenia and is taking an antipsychotic medication. Which of the following screening tools should the nurse use to identify tardive dyskinesia?

Tardive dyskinesia is a potential long-term adverse effect of antipsychotic medications, especially first-generation antipsychotics, caused by prolonged dopamine receptor blockade. It presents with involuntary, repetitive movements such as lip smacking, tongue protrusion, facial grimacing, and abnormal limb movements. Early detection is important because symptoms may become irreversible if not recognized promptly. Standardized assessment tools help nurses monitor clients receiving antipsychotic therapy for extrapyramidal side effects. Rationale: A. Mental Status Examination is used to assess cognitive function, orientation, mood, thought processes, and perception. It helps evaluate psychiatric and neurological status but does not specifically assess involuntary motor movements associated with tardive dyskinesia. It is useful for mental functioning, not movement disorder screening. B. Patient Health Questionnaire-9 (PHQ-9) is a screening tool used to assess the severity of depression by evaluating symptoms such as mood, sleep, appetite, and concentration. It is not designed to detect extrapyramidal side effects or abnormal involuntary movements caused by antipsychotic medications. C. Brief Psychiatric Rating Scale evaluates psychiatric symptoms such as anxiety, depression, hallucinations, and unusual behavior in clients with serious mental illness. It helps monitor psychiatric symptom severity but does not specifically identify tardive dyskinesia or other movement disorders related to medication use. D. Abnormal Involuntary Movement Scale (AIMS) is specifically designed to assess and monitor tardive dyskinesia in clients taking antipsychotic medications. It evaluates involuntary movements of the face, mouth, extremities, and trunk, allowing early recognition of extrapyramidal symptoms. Regular use of AIMS supports prompt intervention and prevention of permanent movement disorders.